Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.50
-0.52 (-0.21%)
AAPL  266.43
+7.60 (2.94%)
AMD  258.12
+3.05 (1.20%)
BAC  54.32
+0.97 (1.82%)
GOOG  334.47
+3.89 (1.18%)
META  671.58
+9.09 (1.37%)
MSFT  411.22
+18.11 (4.61%)
NVDA  198.87
+2.36 (1.20%)
ORCL  169.81
+6.81 (4.18%)
TSLA  391.95
+27.75 (7.62%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.